|
|
Skin biomarkers for diagnosing and characterizing AD and ADRD |
| 1 R01 AG067607-01A1 |
|
NIA |
2021 |
|
|
Decoding the impact of sex differences on Alzheimers disease risk |
| 1 R01 AG074009-01 |
|
NIA |
2021 |
|
|
Repurposing drugs for Alzheimer´s disease using a reverse translational approach |
| 1 RF1 AG067996-01A1 |
|
NIA |
2021 |
|
|
Cerebrovascular involvement in Alzheimers Disease: PAR4 Antagonism |
| 1 RF1 AG068623-01A1 |
|
NIA |
2021 |
|
|
Blood-brain barrier dysfunction in Alzheimers disease: from humans to animal models |
| 1 RF1 AG071515-01 |
|
NIA |
2021 |
|
|
Oligodendrocyte heterogeneity in Alzheimer' s disease |
| 1 RF1 AG071683-01 |
|
NIA |
2021 |
|
|
Applied Physiology and Mechanisms |
| 2 P30 AG028747-16 |
|
NIA |
2021 |
|
|
Characterizing the landscape of cell-type specific changes associated with Alzheimers disease before death with single-cell genomics |
| 5 F30 AG069446-02 |
|
NIA |
2021 |
|
|
Changing the energy substrate balance: Does APOE2 promote glucose usage to protect from Alzheimers Disease? |
| 5 R01 AG062550-03 |
|
NIA |
2021 |
|
|
Non-contrast MR imaging of blood-brain-barrier permeability in Alzheimers disease |
| 5 R01 AG064792-02 |
|
NIA |
2021 |
